[Platelet antiaggregants in cerebral ischemic pathology]

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Context:

• Cerebral ischemia prevention strategies are crucial for reducing stroke incidence.
• Platelet aggregation inhibitors are a primary focus in managing cerebrovascular diseases.
• Atherosclerosis and cardiac conditions like atrial fibrillation are key risk factors for stroke.

Purpose:

• To review the efficacy of platelet aggregation inhibitors in preventing cerebral ischemia.
• To evaluate the current evidence for aspirin and ticlopidine in secondary stroke prevention.
• To discuss the limitations and ongoing research regarding primary stroke prevention and acute treatment.

Summary:

• Aspirin (300 mg/day) and ticlopidine (500 mg/day) demonstrate significant risk reduction (20% and 30% respectively) in secondary prevention of atherosclerotic cerebral ischemic events.
• Current evidence does not support the use of these agents for primary prevention or acute treatment of cerebral infarction.
• Anticoagulants are recommended for preventing thromboembolic stroke of cardiac origin, with ongoing studies assessing aspirin's role in non-valvular atrial fibrillation.

Impact:

• Provides a clear overview of established and emerging therapeutic strategies for cerebral ischemia.
• Highlights the importance of differentiating between primary and secondary stroke prevention.
• Informs clinical practice regarding the appropriate use of antiplatelet agents and anticoagulants in stroke prevention.